Evidence map›Paper›PMID 29572674›Full record

ArticleJournal of neuro-oncology2018

Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Taeryool Koo, Do Hoon Lim, Ho Jun Seol, Chul-Kee Park, Il Han Kim, Jong Hee Chang, Jeongshim Lee, Shin Jung, Ho-Shin Gwak, Kwan Ho Cho and 13 more

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Taeryool KooDepartment of Radiation Oncology, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Do Hoon LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-Ro, Gangnam-Gu, Seoul, 06351, South Korea. dh8lim@skku.edu.ORCID http://orcid.org/0000-0002-5426-0604
Ho Jun SeolDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea.
Il Han KimDepartment of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Jong Hee ChangDepartment of Neurosurgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Jeongshim LeeDepartment of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Shin JungDepartment of Neurosurgery, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Ho-Shin GwakDepartment of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
Kwan Ho ChoProton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
Chang-Ki HongDepartment of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Ik Jae LeeDepartment of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
El KimDepartment of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
Jin Hee KimDepartment of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
Yong-Kil HongDepartment of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Hong Seok JangDepartment of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Chae-Yong KimDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
In Ah KimDepartment of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Sung Hwan KimDepartment of Radiation Oncology, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea.
Young Il KimDepartment of Radiation Oncology, Chungnam National University School of Medicine, Daejeon, South Korea.
Eun-Young KimDepartment of Neurosurgery, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.
Woo Chul KimDepartment of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.
Semie HongDepartment of Radiation Oncology, Konkuk University Medical Center, School of Medicine, Konkuk University, Seoul, South Korea.
Yonsei University · KRKeimyung University Dongsan Medical Center · KRSeoul National University · KRNational Cancer Center · KRSamsung Medical Center · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRChonnam National University Hwasun Hospital · KRChungnam National University · KRHallym University Sacred Heart Hospital · KRInha University Hospital · KRKonkuk University Medical Center · KRSeoul National University Bundang Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe performed this study to identify the treatment patterns of patients with low-grade gliomas (LGG) in Korea.

methodsA total of 555 patients diagnosed as WHO grade II gliomas between 2000 and 2010 at 14 Korean institutions were included. The patients were divided into four adjuvant treatment groups: adjuvant fractionated radiotherapy (RT, N = 204), adjuvant chemotherapy (N = 20), adjuvant fractionated RT and chemotherapy (N = 65), and non-adjuvant treatment (N = 266) groups. We examined differences among the groups and validated patient/tumor characteristics associated with the adjuvant treatments.

resultsAstrocytoma was diagnosed in 210 patients (38%), oligoastrocytoma in 85 patients (15%), and oligodendroglioma in 260 patients (47%). Gross total resection was performed in 200 patients (36%), subtotal resection in 153 (28%), partial resection in 71 patients (13%), and biopsy in 131 patients (24%). RT was most commonly applied as an adjuvant treatment. The use of chemotherapy with or without RT decreased after 2008 (from 38 to 4%). The major chemotherapeutic regimen was procarbazine, lomustine, and vincristine (PCV); however, the proportion of temozolomide increased since 2005 (up to 69%). Patient/tumor characteristics related with RT were male gender, non-seizure, multiple lobes involvement, and non-gross total resection. Chemotherapy was associated with non-gross total resection and non-astrocytoma.

conclusionsA preference for RT and increased use of temozolomide was evident in the treatment pattern of LGG. The extent of resection was associated with a decision to perform RT and chemotherapy. To establish a robust guideline for LGG, further studies including molecular information are needed.

Indexed as

Practice Patterns, Physicians'AdultAgedBrain NeoplasmsCerebral CortexFemaleGliomaHumansMaleMiddle AgedNeoplasm GradingRepublic of KoreaRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultLow-grade gliomaPatterns of carePCVRadiotherapyTemozolomide

Identifiers

PMID29572674
OpenAlexW2789286177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.